ALGS - Aligos Therapeutics, Inc.

6.98
0.320   4.585%

Share volume: 87,186
Last Updated: 03-06-2026
Pharmaceutical Products/Biological Products, Except Diagnostic Substances: 0.19%

PREVIOUS CLOSE
CHG
CHG%
$6.66
0.32
0.05%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
39%
Profitability 43%
Dept financing 33%
Liquidity 58%
Performance 33%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
0.22%
1 Month
-3.46%
3 Months
-35.25%
6 Months
-37.17%
1 Year
-46.06%
2 Year
650.54%
Key data
Stock price
$6.98
P/E Ratio 
0.00
DAY RANGE
$6.36 - $7.37
EPS 
-$14.10
52 WEEK RANGE
$3.76 - $13.69
52 WEEK CHANGE
-$32.95
MARKET CAP 
120.567 M
YIELD 
N/A
SHARES OUTSTANDING 
15.725 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
05-06-2025
BETA 
-0.14
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$45,999
AVERAGE 30 VOLUME 
$42,509
Company detail
CEO: Lawrence M. Blatt
Region: US
Website: www.aligos.com
Employees: 90
IPO year: 2020
Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Biological Products, Except Diagnostic Substances
Sector: Manufacturing

Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses to develop novel therapeutics to address unmet medical needs in viral and liver diseases. Its lead drug candidate is ALG-010133, a s-antigen transport-inhibiting oligonucleotide polymer that is in Phase Ib clinical trial for the treatment of chronic hepatitis B (CHB)

Recent news